Chapter 25
Molecular–Docking–Based Drug Design and Discovery:
Rational Drug Design for the Subtype Selective GPCR Ligands

Soo-Kyung Kim
California Institute of Technology, USA

William A. Goddard III
California Institute of Technology, USA

ABSTRACT

Currently 30-50% of drug targets are G Protein-Coupled Receptors (GPCRs). However, the clinical useful drugs for targeting GPCR have been limited by the lack of subtype selectivity or efficacy, leading to undesirable side effects. To develop subtype-selective GPCR ligands with desired molecular properties, better understanding is needed of the pharmacophore elements and of the binding mechanism required for subtype selectivity. To illustrate these issues, we describe here three successful applications to understand the binding mechanism associated with subtype selectivity: 5-HT2B (5-Hydroxytryptamine, 5-HT) serotonin receptor ($HT_{2B}R$), H_3 histamine receptor (H_3HR) and A_3 adenosine receptor (A_3AR). The understanding of structure-function relationships among individual types and subtypes of GPCRs gained from such computational predictions combined with experimental validation and testing is expected the development of new highly selective and effective ligands to address such diseases while minimizing side-effects.

INTRODUCTION

G protein-coupled receptors (GPCRs) with >800 including 340 non-olfactory receptors are the largest superfamily in the human genome. These are customarily partitioned into 5 families: glutamate, rhodopsin, adhesion, frizzled, and secretin (Fredriksson, Lagerstrom, Lundin, & Schioth, 2003). GPCRs regulate essential physiological processes (e.g. cellular metabolism, cell growth, secretion, immune

defense, neurotransmission, and differentiation) through various endogenous ligands which include biogenic amines, peptides, lipids, nucleotides, and proteins, modulate (Lefkowitz, Pierce, & Luttrell, 2002). GPCRs also involves in various important cell recognition and communication processes (Ellis, 2004). Thus, GPCRs are important drug targets for all major disease areas, including neurodegenerative, psychiatric, metabolic, cardiovascular, cancer, and infectious diseases (Tang & Insel, 2005). Indeed, currently 30-50% of drug targets are GPCRs (Hopkins & Groom, 2002). The currently marked GPCR-targeting drugs with ~80 account for ~$50 billion in annual sales, and many have annual sales > $2 billion (Goddard III & Abrol, 2007). Identifying GPCR subtypes with specific cell and tissue has been accelerated for target evaluation, lead identification, and optimization of GPCRs. However, the clinical use as drugs for targeting GPCR have been limited by the lack of subtype selectivity or efficacy, leading to undesirable side effects.

BACKGROUND

Endogenous ligands regulate multiple GPCR subtypes. Serotonin activates 15 serotonin (5-HT) receptors. With the exception of the 5-HT_3 receptor, a ligand-gated ion channel, all other 14 serotonin receptors are GPCRs. The 5-HT_1 (1A- 1F) and 5-HT_5 (5A, 5B) receptors decrease cellular level of cAMP through coupling with Gi/ Go protein, while 5HT_4, 5-HT_6, and 5-HT_7 receptors increase cellular level of cAMP through coupling with Gs protein. 5-HT_2 (2A– 2C) receptors increase cellular level of inositol triphosphate (IP_3) and diacylglycerol (DAG) through coupling with G_q/ G_{11} protein (Nichols & Nichols, 2008). Various biological and neurological processes were regulated through the serotonin receptors such as aggression, anxiety, appetite, cognition, learning, memory, mood, nausea, sleep, and thermoregulation. Thus, the serotonin receptors are the target of a variety of pharmaceutical drugs, including many antidepressants, antipsychotics, anorectics, antiemetics, gastroprokinetic agents, antimigraine agents, hallucinogens, and entactogens (Nichols & Nichols, 2008).

Histamine acts via four histamine receptors (HRs); H_1, H_2, H_3 and H_4. Histamine has a critical role in immumomodulation and allergic diseases. Other biological activities include cell proliferation, differentiation, hematopoiesis, embryonic development, regeneration, wound healing, aminergic neurotransmission, secretion of pituitary hormones and regulation of gastrointestinal and circulatory functions (Jutel, Blaser, & Akdis, 2005). The H_3 and H_4 HRs inhibit the cellular level of cAMP through coupling with Gi/ Go protein, while the H_2HR activates the cellular level of cAMP through coupling with Gs protein. The H_1HR increases the cellular level of IP_3 and DAG through coupling with G_q/ G_{11} protein.

Adenosine binds all 4 subtypes of adenosine receptors (ARs), denoted A_1, A_{2A}, A_{2B}, and A_3, which coupled to G proteins. Activation of the A_1 and A_3 ARs inhibit the cellular level of cAMP via Gi/ Go protein, while the A_{2A} and A_{2B} ARs activate the cellular level of cAMP via Gs protein (Olah & Stiles, 1995). ARs are involved in many of the body's cytoprotective functions. Thus, ARs are important pharmacological targets in the treatment of a variety of diseases because of their key roles in controlling numerous physiological processes. For example, many therapeutic agents under development for treatment of central nervous system disorders, inflammatory diseases, asthma, kidney failure and ischemic injuries exert their effects via interactions with ARs.

To achieve high selectivity for specific GPCR subtype, an alternative approach is the development of selective allosteric modulators of the specific receptor subtypes. There are two marketed GPCR allosteric modulators, a positive allosteric modulator of the calcium sensing receptor used to treat hyperparathy-

Related Content

QSAR Studies on Bacterial Efflux Pump Inhibitors
Khac-Minh Thai, Trong-Nhat Do, Thuy-Viet-Phuong Nguyen, Duc-Khanh-Tho. Nguyenand Thanh-Dao Tran (2015). *Quantitative Structure-Activity Relationships in Drug Design, Predictive Toxicology, and Risk Assessment (pp. 238-268).*
www.irma-international.org/chapter/qsar-studies-on-bacterial-efflux-pump-inhibitors/124472

A Review on the Effect of Green Synthesized Silver Nanoparticles Using Natural Products on Triple Negative Breast Cancer
Angellin Priscilla Selvakumar, Prathibha K. Sivaprakasam, Kumaran Sekarand Ashok Kumar Pandurangan (2023). *Natural Products as Cancer Therapeutics (pp. 162-175).*
www.irma-international.org/chapter/a-review-on-the-effect-of-green-synthesized-silver-nanoparticles-using-natural-products-on-triple-negative-breast-cancer/329158

Cosmeceuticals: Safety, Efficacy and Potential Benefits
Long Chiau Ming, Wei Chern Ang, Quan Yang, Premrutai Thitilertdecha, Tin Wui Wongand Tahir Mehmood Khan (2017). *Recent Advances in Drug Delivery Technology (pp. 287-308).*
www.irma-international.org/chapter/cosmeceuticals/164024

Flavonoids: Prospective Strategy for the Management of Diabetes and Its Associated Complications
Vineet Mehtaand Udayabanu Malairaman (2017). *Pharmaceutical Sciences: Breakthroughs in Research and Practice (pp. 569-612).*
www.irma-international.org/chapter/flavonoids/174141

Antidiabetic Activity (Anti-Hyperglycemic Activity, Anti-Hyperlipidemic Activity)/Agents From Medicinal Plants
Manish Singh Sansi, Daraksha Iram, Kapil Singh Narayan, Sandeep Kumar, Om Prakashand Dipanjan Misra (2020). *Advanced Pharmacological Uses of Medicinal Plants and Natural Products (pp. 25-48).*
www.irma-international.org/chapter/antidiabetic-activity-anti-hyperglycemic-activity-anti-hyperlipidemic-activityagents-from-medicinal-plants/252934